Pharming Announces That The U.K. Medicines And Healthcare Products Regulatory Agency Has Granted Marketing Authorization For Joenja For The Treatment Of Activated Phosphoinositide 3-kinase Delta Syndrome
Portfolio Pulse from Benzinga Newsdesk
Pharming has received marketing authorization from the U.K. Medicines and Healthcare Products Regulatory Agency for Joenja, a treatment for Activated Phosphoinositide 3-kinase Delta Syndrome.
September 26, 2024 | 6:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pharming has been granted marketing authorization in the U.K. for Joenja, a treatment for Activated Phosphoinositide 3-kinase Delta Syndrome, potentially boosting its market presence and revenues.
The marketing authorization for Joenja in the U.K. is a significant regulatory milestone for Pharming, likely to enhance its market presence and drive revenue growth. This positive development is expected to have a favorable impact on Pharming's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100